Oncology/Hematology Archives | Page 6 of 12 | Certara

Blog

Using M&S to Evaluate Oncology Drug Dosing

There are numerous challenges in developing oncology drugs: (1) they are often very toxic which…

CertaraApril 13, 2018

Publication

An Analysis on Distribution and Inter-relationships of Biomarkers Under Rivaroxaban in Japanese Patients with Non-valvular Atrial Fibrillation (CVI ARO 1)

CertaraMarch 15, 2018

Publication

A Randomized, Controlled Trial Evaluating the Efficacy and Safety of BTH1677 in Combination with Bevacizumab, Carboplatin, and Paclitaxel in First-line Treatment of Advanced Non-small Cell Lung Cancer

CertaraFebruary 27, 2018

Publication

Incorporation of GSTA1 Genetic Variations into a Population Pharmacokinetic Model for IV Busulfan in Pediatric Hematopoietic Stem Cell Transplantation

CertaraFebruary 22, 2018

Blog

Surveying the Lay of the Land for Modeling & Simulation for Global Regulatory Submissions

Analogous to how a geologist surveys the “lay of the land” to determine if oil…

CertaraFebruary 16, 2018

Publication

Model-informed Drug Development for Ixazomib, an Oral Proteasome Inhibitor

CertaraFebruary 15, 2018

Publication

Exposure-response of Veliparib to Inform Phase 2 Trial Design in Refractory or Relapsed Patients with Hematological Malignancies

CertaraNovember 1, 2017

Publication

Clinical Pharmacology Tools and Evaluations to Facilitate Comprehensive Dose Finding in Oncology: A Continuous Risk-Benefit Approach

CertaraSeptember 15, 2017

Publication

Parent‐metabolite Pharmacokinetic Modeling and Pharmacodynamics of Veliparib (ABT‐888), a PARP Inhibitor, in Patients with BRCA 1/2–mutated Cancer or PARP‐sensitive Tumor Types

CertaraAugust 1, 2017

Publication

Response Analysis of Alvocidib (Flavopiridol) Treatment by Bolus or Hybrid Administration in Newly Diagnosed or Relapsed/Refractory Acute Leukemia Patients

CertaraJuly 15, 2017

© 2025 Certara. All Rights Reserved. | Privacy policy